I think we feel like we're well, I'll say, set up to execute. A lot of the cost savings that will continue to fall through in the second half have been continuing to be in flight and happen to be more on the operating expense side. Certainly at the factory level, we have that capacity to grow here in the second half and be established to go into 2025. So I don't really see that as a risk for us. We've been managing this very closely and have good line of sight. And Matt, I wouldn't think about it as cost reduction. It's more like we are now in a mode where we put a lot more focus on productivity and, you know, insourcing because of all the deals we've done over the last nine or ten years. That gives us opportunities to reduce internal costs. So it's kind of a bigger picture of cost reduction, but there's a lot of positive things going on internally in the company that are more productivity-related, insourcing-related. You know, just looking at supplier management, all of those things help towards - and improving margin profiles for the company.

Jul 30, 2024 / receipt, needs a key / Tony Hunt, CFO | earnings call 2024-07-30 | transcript 2b4fff3a-f52a-436c-993a-4930b258d98f | chars 48241-49301 | segment 49

APAC led all geographies along with strong demand in North America

ir_statement / Sep 17, 2026 / receipt

disciplined cost management

ir_statement / Sep 17, 2026 / receipt

Raising organic revenue growth guidance to 10.5%-13.5%

ir_statement / Sep 17, 2026 / receipt

Adjusted operating income and margin guidance increased due to strong 1H performance

ir_statement / Sep 17, 2026 / receipt

Expect sequential OpEx increase driven by normalized spending and 2H investments to support 2027 growth

ir_statement / Sep 17, 2026 / receipt

Strong 1H results allow us to increase both organic growth and adj. EPS guidance

ir_statement / Sep 17, 2026 / receipt

Charges for the three and six months ended June 30, 2026, consists of activities to simplify the global manufacturing footprint of the organization and align its workforce to support long-term company

ir_statement / Sep 17, 2026 / receipt

transformation costs include $3.8 million and $4.8 million, respectively, of expenses for discrete strategic projects that are designed to deliver long-term growth under our Transformation Office

ir_statement / Sep 17, 2026 / receipt

Grow with customers trials

ir_statement / Sep 17, 2026 / receipt

Key account penetration in large pharma & CDMO’s

ir_statement / Sep 17, 2026 / receipt

Hired new head of APAC and GM of China in 2025

ir_statement / Sep 17, 2026 / receipt

Key accounts focused on partnering with ~20 large Pharma’s & CDMO’s … significantly accretive to growth since launch

ir_statement / Sep 17, 2026 / receipt